GLP-1 and Cardiac Panel: Heart Monitoring
How GLP-1 medications protect your heart -- and the tests that prove it.
The SELECT trial proved what obesity medicine specialists had long suspected: semaglutide does not just help you lose weight -- it directly protects your heart. Cardiac monitoring on GLP-1 medications documents these improvements and guides treatment decisions.
Recommended Cardiac Panel
Cardiac Lab Tests
| Test | What It Measures | Typical GLP-1 Effect |
|---|---|---|
| LDL cholesterol | Atherogenic lipid | 15-25% decrease at 12 months |
| Triglycerides | Blood fat | 25-40% decrease |
| HDL cholesterol | Protective lipid | 5-10% increase |
| ApoB | Atherogenic particle count | Decreases with weight loss |
| Lp(a) | Genetic CV risk marker | Usually unchanged (genetic) |
| hs-CRP | Vascular inflammation | 40-60% decrease |
| NT-proBNP | Heart failure marker | Decreases with weight loss |
SELECT Trial: The Cardiac Evidence
The landmark SELECT trial enrolled 17,604 adults with overweight/obesity and established cardiovascular disease (without diabetes). Results: 20% reduction in major adverse cardiovascular events (MACE), significant reductions in heart attack and stroke risk, improvements in heart failure symptoms, and benefits independent of diabetes status. This was the first obesity medication to demonstrate direct cardiovascular protection.
Who Needs a Cardiac Panel?
Cardiac Testing Recommended For
- Patients with known cardiovascular disease
- Family history of premature heart disease
- Diabetes or prediabetes
- Hypertension
- Elevated baseline lipids or CRP
- Smokers or former smokers
- Men over 45 or women over 55
Protect Your Heart
GLP-1 treatment with cardiac monitoring. Semaglutide $99/mo. Tirzepatide $125/mo through Trimi.
Get StartedMedical Disclaimer
Cardiac monitoring recommendations vary by individual risk. Discuss cardiovascular testing with your healthcare provider. Do not adjust cardiac medications without physician guidance.
More on GLP-1 lab monitoring
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).